ICL Group Ltd. - ICL STOCK NEWS

ICL (NYSE: ICL), a global leader in specialty minerals, announced during its Investor Day plans to enhance its specialty businesses, targeting over $2 billion in EBITDA by 2027—a 100% increase from 2021. The company aims for a 16% CAGR, driven by its Industrial Products, Phosphate Specialties, and Growing Solutions divisions. CEO Raviv Zoller highlighted the significant growth opportunities amid sustainability challenges. Detailed targets will be shared at the event, with a replay available online shortly after.

ICL has launched ICLeaf, a diagnostics tool for farmers that analyzes leaf samples to maximize crop yields. This innovative tool measures 10 elements and provides real-time nutrient feedback within three days, significantly faster than traditional methods. Currently available for crops like grape and cotton in India, it complements Crop Advisor, enhancing personalized nutrient management. Developed by Agmatix, the tool underscores ICL's commitment to sustainable agriculture, aiming to assist farmers in making informed, in-season decisions for improved yield and profitability.

ICL has announced plans to construct a $400 million lithium iron phosphate (LFP) cathode active material manufacturing plant in St. Louis. The project will receive $197 million in federal funding from the Bipartisan Infrastructure Law, pending negotiations with the Department of Energy. The facility aims to be operational by 2024 and produce 30,000 metric tons of LFP material annually. This expansion is a strategic move to meet the growing demand for lithium batteries, especially for electric vehicles, and to enhance ICL's energy storage portfolio.

ICL, a global leader in specialty minerals, has announced the release of its third quarter 2022 results, scheduled for November 9, 2022, prior to the TASE market opening. The company will hold a conference call at 8:30 a.m. New York time to discuss these results, alongside a business update. Additionally, ICL is hosting an Investor Day on October 25, where it will outline updated growth targets, although no third quarter results will be provided. Registered analysts, employees, and the public can join the call, with a replay available shortly after.

ICL announces its virtual 2022 Investor Day scheduled for October 25, where leadership will share updated targets for long-term growth in specialty products. The event will feature insights from Raviv Zoller, President and CEO, and Aviram Lahav, CFO, alongside the senior management team. ICL, a leading global specialty minerals company, reported revenues of approximately $7 billion in 2021 and employs over 12,000 individuals worldwide.

For further details, visit ICL's investor relations page.

ICL has launched eqo.x, a revolutionary rapidly biodegradable release technology for urea fertilizers aimed at enhancing sustainable agriculture. This new controlled release fertilizer (CRF) technology is designed to meet the EU's 2026 fertilizer standards, improving nutrient use efficiency by up to 80% and supporting higher crop yields with reduced fertilizer application. ICL is investing $20 million in a new production line in the Netherlands to meet market demand. The global controlled release fertilizer market is projected to grow from $2.3 billion in 2018 to $3.86 billion by 2026.

ICL announces a $10 million investment in Lavie Bio, a subsidiary of Evogene, as part of a strategic collaboration. This multi-year partnership aims to develop novel bio-stimulant products to enhance fertilizer efficiency, leveraging Lavie Bio's expertise in ag-biologicals and ICL's knowledge in fertilizer use. The ag-biologicals market, valued at $7.42 billion in 2018, is projected to reach $20.59 billion by 2026, indicating substantial growth potential. The collaboration aligns with ICL’s sustainability goals and market expansion in the ag-biologicals segment.

ICL (NYSE: ICL, TASE: ICL), a global leader in specialty minerals, announced that Philip Brown, the president of ICL Phosphate Specialties, will present at the Jefferies Virtual Industrials Conference on August 10, 2022, at 10 a.m. ET.

A webcast of the presentation will be available at ICL's investor site. The company reported revenues of approximately $7 billion in 2021 and employs over 12,000 people worldwide.

ICL reported strong financial results for Q2 2022, with consolidated sales of $2,880 million, up 78% year-over-year. Operating income soared 369% to $1,139 million, and net income reached $563 million, a 302% increase. Adjusted EBITDA rose 249% to $1,258 million, achieving an EBITDA margin of 43.7%. The company raised its full-year adjusted EBITDA forecast to $3,800-$4,000 million. A tax settlement with the Israeli Tax Authority led to recognized tax expenses of $188 million. A dividend of 29.18 cents per share was also declared.